What is Orthofix Medical Inc.'s earnings per share (EPS)?

Orthofix Medical Inc. (OFIX) reported diluted earnings per share of -$2.33 for fiscal year 2025. This represents a 29.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Orthofix Medical Inc. (OFIX) Financials

OFIX

Trailing 12 months to June 30, 2026

Revenue $833.2M +3.0% YoY

Net Income -$61.7M +50.1% YoY

EPS (Diluted) -$1.53 +51.7% YoY

Free Cash Flow -$27.8M -6135.6% YoY

Market Cap $373.5M as of Oct 10, 2026

Price / Sales 0.4x on $833.2M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 0.9x on $429.2M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 5, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OFIX SEC filings page.

Orthofix Medical Inc. (OFIX) reported $833.2M in revenue over the twelve months to Jun 30, 2026, up 3.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI OFIX FY2025 2026-10-03

Orthofix is nearing cash neutrality, but its enlarged revenue base still does not cover a heavy operating-cost structure.

Revenue reached $822M in FY2025 while gross margin recovered to 68.8%, indicating better gross economics at the product level. Yet the operating margin remained -9.9%, showing that the improved gross profit still cannot absorb the company’s broader expense base.

Accounting losses are not translating into equivalent operating cash outflows: FY2025 operating cash flow was positive at $33M despite a net loss of $92M. However, capital spending of $35M left free cash flow at -$1.3M, so cash conversion is currently being consumed by reinvestment.

The balance sheet remains supported by a current ratio of 2.4x, but leverage has risen as debt-to-equity moved from 0.2x in FY2023 to 0.3x in FY2025. Equity fell to $450M while long-term debt reached $157M, linking persistent losses with a more debt-dependent capital structure.

Financial Health Signals

Financial Health Score 43/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Orthofix Medical Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Orthofix Medical Inc. has an operating margin of -9.9%, meaning the company loses $10 on every $100 of revenue. This results in a profitability score of 26/100. This is up from -10.6% the prior year.

Growth

Orthofix Medical Inc.'s revenue grew a modest 2.9% year-over-year to $822.3M. This slow but positive growth earns a score of 50/100.

Leverage

Orthofix Medical Inc. carries a low D/E ratio of 0.35, meaning only $0.35 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 67/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 2.45, Orthofix Medical Inc. holds $2.45 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 70/100.

Cash Flow

While Orthofix Medical Inc. generated $33.3M in operating cash flow, capex of $34.6M consumed most of it, leaving -$1.3M in free cash flow. This results in a low score of 18/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Orthofix Medical Inc. posts a -20.5% return on equity (ROE), meaning it loses $20 for every $100 of shareholders' equity. This results in a returns score of 25/100. This is up from -25.0% the prior year.

Altman Z-Score Distress

0.95

Orthofix Medical Inc. scores 0.95, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($373.5M) relative to total liabilities ($400.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

5/9

Orthofix Medical Inc. passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Mixed

N/A

Orthofix Medical Inc. reported a net loss of $92.2M while generating $33.3M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Orthofix Medical Inc. reported an operating loss of $81.4M against $17.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$210.9M

YoY+3.8%

QoQ+7.2%

5Y CAGR+11.7%

10Y CAGR+7.3%

Orthofix Medical Inc. generated $210.9M in revenue in Q2 2026. This represents an increase of 3.8% from the same quarter a year earlier. Against the prior quarter it is up 7.2%.

EBITDA

$5.1M

YoY+492.1%

QoQ+645.0%

5Y CAGR-15.4%

Orthofix Medical Inc.'s EBITDA was $5.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 492.1% from the same quarter a year earlier. Against the prior quarter it is up 645.0%.

Net Income

-$15.8M

YoY-12.2%

QoQ+24.4%

Orthofix Medical Inc. reported -$15.8M in net income in Q2 2026. This represents a decrease of 12.2% from the same quarter a year earlier. Against the prior quarter it is up 24.4%.

EPS (Diluted)

-$0.39

YoY-8.3%

QoQ+25.0%

Orthofix Medical Inc. earned -$0.39 per diluted share (EPS) in Q2 2026. This represents a decrease of 8.3% from the same quarter a year earlier. Against the prior quarter it is up 25.0%.

Cash & Balance Sheet

Free Cash Flow

-$18.9M

YoY-516.6%

QoQ+33.2%

Orthofix Medical Inc. recorded an outflow of $18.9M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 516.6% from the same quarter a year earlier. Against the prior quarter it is up 33.2%.

Cash & Debt

$103.8M

YoY+58.2%

QoQ-13.7%

5Y CAGR+5.4%

10Y CAGR+9.9%

Orthofix Medical Inc. held $103.8M in cash against $221.6M in long-term debt as of Q2 2026.

Shares Outstanding

41M

YoY+3.1%

QoQ+0.8%

5Y CAGR+15.6%

10Y CAGR+8.4%

Orthofix Medical Inc. had 41M shares outstanding in Q2 2026. This represents an increase of 3.1% from the same quarter a year earlier. Against the prior quarter it is up 0.8%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

71.0%

YoY+2.3pp

QoQ0.0pp

5Y change-6.4pp

10Y change-7.4pp

Orthofix Medical Inc.'s gross margin was 71.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.3 percentage points from the same quarter a year earlier. It is unchanged from the prior quarter.

Operating Margin

-3.9%

YoY+4.0pp

QoQ+3.5pp

5Y change-7.4pp

10Y change-1.3pp

Orthofix Medical Inc.'s operating margin was -3.9% in Q2 2026, reflecting core business profitability. This is up 4.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.5 percentage points.

Net Margin

-7.5%

YoY-0.6pp

QoQ+3.1pp

5Y change-9.5pp

10Y change-0.3pp

Orthofix Medical Inc.'s net profit margin was -7.5% in Q2 2026, showing the share of revenue converted to profit. This is down 0.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.1 percentage points.

Return on Equity

-3.7%

YoY-0.6pp

QoQ+1.1pp

5Y change-4.3pp

10Y change-0.8pp

Orthofix Medical Inc.'s ROE was -3.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 0.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.

Capital Allocation

R&D Spending

$15.9M

YoY+0.1%

QoQ+4.1%

5Y CAGR+4.0%

Orthofix Medical Inc. invested $15.9M in research and development in Q2 2026. This represents an increase of 0.1% from the same quarter a year earlier. Against the prior quarter it is up 4.1%.

Capital Expenditures

$12.6M

YoY+77.9%

QoQ+18.6%

5Y CAGR+22.0%

10Y CAGR+13.7%

Orthofix Medical Inc. invested $12.6M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 77.9% from the same quarter a year earlier. Against the prior quarter it is up 18.6%.

Share Buybacks

Not reported for Q2 2026.

OFIX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OFIX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$833.2M	$822.3M+2.9%	$799.5M+7.1%	$746.6M+62.1%	$460.7M-0.8%	$464.5M+14.2%	$406.6M-11.6%	$460.0M+1.5%	$453.0M+4.4%	$433.8M+5.9%	$409.8M+3.4%	$396.5M-1.4%	$402.3M+1.2%	$397.6M-9.7%	$440.2M+1.1%	$435.5M
Cost of Revenue	$239.1M	$256.3M+1.1%	$253.6M-2.6%	$260.4M+110.7%	$123.5M+7.5%	$114.9M+12.8%	$101.9M+1.3%	$100.6M+4.1%	$96.6M+3.9%	$93.0M+5.9%	$87.9M+1.5%	$86.5M-12.5%	$98.9M-7.5%	$106.9M+6.1%	$100.7M+4.5%	$96.4M
Gross Profit	$594.1M	$566.0M+3.7%	$545.9M+12.3%	$486.3M+44.2%	$337.2M-3.5%	$349.6M+14.7%	$304.7M-15.2%	$359.3M+0.8%	$356.4M+4.6%	$340.8M+5.9%	$321.9M+3.9%	$310.0M+2.2%	$303.4M+4.4%	$290.7M-14.4%	$339.5M+0.1%	$339.1M
R&D Expenses	$61.4M	$65.8M-10.6%	$73.6M-8.2%	$80.2M+63.5%	$49.1M-1.1%	$49.6M+27.1%	$39.1M+12.8%	$34.6M+4.3%	$33.2M+11.8%	$29.7M+3.1%	$28.8M+9.1%	$26.4M+5.6%	$25.0M-6.6%	$26.8M-6.3%	$28.6M+25.0%	$22.9M
SG&A Expenses	$557.8M	$554.3M+4.1%	$532.5M+0.4%	$530.4M+71.8%	$308.8M+345.2%	$69.4M+2.1%	$67.9M-20.6%	$85.6M+2.8%	$83.3M+15.8%	$71.9M-5.9%	$76.4M-12.3%	$87.2M+10.2%	$79.1M+17.1%	$67.5M+25.8%	$53.6M-17.2%	$64.8M
Operating Income	-$39.1M	-$81.4M+3.8%	-$84.6M+39.2%	-$139.1M-948.5%	-$13.3M-59.6%	-$8.3M-32.7%	-$6.3M+66.6%	-$18.8M-162.4%	$30.1M-26.3%	$40.8M+93.7%	$21.1M+127.6%	$9.3M-46.0%	$17.1M+253.1%	-$11.2M-114.9%	$74.9M+1032.5%	$6.6M
EBITDA	N/A	-$4.1M+83.3%	-$24.6M+71.5%	-$86.0M-646.3%	$15.8M-26.0%	$21.3M-12.3%	$24.3M+310.5%	$5.9M-87.9%	$48.8M-20.0%	$60.9M+45.4%	$41.9M+38.9%	$30.2M-24.6%	$40.0M+244.1%	$11.6M-87.5%	$93.2M+212.7%	$29.8M
Interest Expense	-$20.8M	-$17.5M+41.0%	-$29.6M-243.3%	-$8.6M-570.1%	-$1.3M+29.9%	-$1.8M+26.0%	-$2.5M-1935.2%	-$122K+85.3%	-$828K-99.0%	-$416K-154.5%	$763K+256.0%	-$489K-127.4%	$1.8M-2.3%	$1.8M-56.1%	$4.2M-23.5%	$5.4M
Income Tax	$1.4M	$1.4M-34.9%	$2.1M-21.9%	$2.7M+32.9%	$2.0M-91.8%	$24.9M+962.5%	-$2.9M-304.2%	$1.4M-84.4%	$9.1M-68.8%	$29.1M+87.4%	$15.5M+43.1%	$10.8M-33.0%	$16.2M+113.1%	$7.6M-68.3%	$23.9M+65.8%	$14.4M
Net Income	-$61.7M	-$92.2M+26.8%	-$126.0M+16.8%	-$151.4M-666.6%	-$19.8M+48.5%	-$38.4M-1624.8%	$2.5M+108.8%	-$28.5M-306.1%	$13.8M+121.9%	$6.2M+103.6%	$3.1M+208.8%	-$2.8M+67.1%	-$8.5M+70.4%	-$28.8M-167.2%	$42.9M+342.1%	-$17.7M
EPS (Basic)	N/A	-$2.33+29.4%	-$3.30+19.9%	-$4.12-320.4%	-$0.98+49.7%	-$1.95-1600.0%	$0.13+108.6%	-$1.51-306.8%	$0.73+114.7%	$0.34+100.0%	$0.17+213.3%	-$0.15+67.4%	-$0.46+70.1%	-$1.54-168.1%	$2.26+333.0%	-$0.97
EPS (Diluted)	-$1.53	-$2.33+29.4%	-$3.30+19.9%	-$4.12	-$0.98	-$1.95-1600.0%	$0.13+108.6%	-$1.51-309.7%	$0.72+111.8%	$0.34+100.0%	$0.17+213.3%	-$0.15+67.4%	-$0.46+70.1%	-$1.54-169.7%	$2.21+327.8%	-$0.97
Diluted Shares (Avg)	N/A	40M+3.9%	38M+3.8%	37M	20M	20M+1.5%	19M+2.6%	19M0.0%	19M+2.2%	18M+0.2%	18M-1.8%	19M+1.8%	18M-1.3%	19M-3.6%	19M+6.4%	18M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$210.9M+3.8%	$196.7M+1.6%	$219.9M+2.0%	$205.6M+4.6%	$203.1M+2.3%	$193.6M+2.7%	$215.7M+7.6%	$196.6M+6.8%
Cost of Revenue	$61.2M-3.7%	$57.2M-20.6%	$63.6M-4.9%	$57.1M-7.2%	$63.6M-0.4%	$72.0M+17.4%	$66.8M+4.8%	$61.6M-4.2%
Gross Profit	$149.7M+7.3%	$139.5M+14.7%	$156.3M+5.0%	$148.5M+10.0%	$139.5M+3.6%	$121.6M-4.4%	$148.8M+8.9%	$135.1M+12.8%
R&D Expenses	$15.9M+0.1%	$15.3M-22.5%	$15.4M-18.3%	$14.8M-14.6%	$15.9M-11.7%	$19.8M+1.4%	$18.8M-0.7%	$17.3M-6.8%
SG&A Expenses	$138.0M+1.1%	$134.9M+1.5%	$136.8M+0.2%	$148.1M+13.8%	$136.5M+1.7%	$133.0M+1.0%	$136.5M-67.5%	$130.1M+379.6%
Operating Income	-$8.1M+49.2%	-$14.4M+70.5%	$494K+104.3%	-$17.0M+9.8%	-$16.0M+35.7%	-$48.9M-66.6%	-$11.5M+37.3%	-$18.9M+22.7%
EBITDA	$5.1M+492.1%	-$943K+93.5%	$13.6M+200.5%	-$4.1M-10.2%	$868K+108.0%	-$14.4M+0.2%	$4.5M+203.9%	-$3.7M+67.2%
Interest Expense	-$6.1M-54.1%	-$5.7M-25.7%	-$4.4M+70.8%	-$4.7M+10.2%	-$4.0M+20.1%	-$4.5M+1.1%	-$14.9M-231.6%	-$5.2M-230.6%
Income Tax	$801K+664.1%	$74K-92.3%	$30K+105.3%	$533K-29.0%	-$142K-113.1%	$961K+12.9%	-$564K-551.2%	$751K+59.1%
Net Income	-$15.8M-12.2%	-$20.9M+60.6%	-$2.2M+92.4%	-$22.8M+16.8%	-$14.1M+57.9%	-$53.1M-47.4%	-$29.1M-31.4%	-$27.4M+5.1%
EPS (Basic)	-$0.39-8.3%	-$0.52+61.5%	-$0.05+93.3%	-$0.57+19.7%	-$0.36+59.1%	-$1.35-42.1%	-$0.75-27.1%	-$0.71+7.8%
EPS (Diluted)	-$0.39-8.3%	-$0.52+61.5%	-$0.05+93.3%	-$0.57+19.7%	-$0.36+59.1%	-$1.35-42.1%	-$0.75-27.1%	-$0.71+7.8%
Diluted Shares (Avg)	41M+3.6%	40M+3.2%	N/A	40M+3.3%	40M+3.9%	39M+3.8%	N/A	38M+3.3%

OFIX Balance Sheet

OFIX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$850.6M-4.8%	$893.3M-3.5%	$925.3M+101.8%	$458.6M-3.8%	$476.6M-9.4%	$525.9M+6.1%	$495.6M+6.2%	$466.6M+15.1%	$405.4M+8.9%	$372.1M-7.0%	$400.2M+1.8%	$393.0M-4.6%	$412.0M-11.3%	$464.5M-32.2%	$685.4M
Current Assets	$416.8M-3.8%	$433.3M+3.1%	$420.4M+64.2%	$256.0M-5.0%	$269.5M-0.3%	$270.4M+3.8%	$260.6M+6.5%	$244.6M-2.8%	$251.8M+29.5%	$194.4M-8.4%	$212.3M-3.1%	$219.0M-17.4%	$265.1M-11.8%	$300.6M-43.4%	$531.1M
Cash & Equivalents	$82.0M-1.5%	$83.2M+151.4%	$33.1M-34.7%	$50.7M-42.3%	$87.8M-8.8%	$96.3M+38.1%	$69.7M+0.1%	$69.6M-14.2%	$81.2M+105.1%	$39.6M-37.8%	$63.7M+72.9%	$36.8M+27.3%	$28.9M-6.0%	$30.8M-6.0%	$32.7M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$172.3M-9.0%	$189.5M-14.7%	$222.2M+121.8%	$100.2M+20.7%	$83.0M-2.0%	$84.6M+2.7%	$82.4M+7.2%	$76.8M-5.5%	$81.3M+28.4%	$63.3M+10.0%	$57.6M-3.8%	$59.8M-17.7%	$72.7M+4.1%	$69.8M-14.4%	$81.5M
Accounts Receivable	$135.7M+0.8%	$134.7M+5.2%	$128.1M+54.6%	$82.9M+5.5%	$78.6M+8.5%	$72.4M-16.6%	$86.8M+11.7%	$77.7M+22.6%	$63.4M+9.7%	$57.8M-3.3%	$59.8M-2.5%	$61.4M-13.3%	$70.8M-31.8%	$103.8M+3.9%	$99.9M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$194.9M0.0%	$194.9M0.0%	$194.9M+173.3%	$71.3M0.0%	$71.3M-15.1%	$84.0M+18.0%	$71.2M-1.7%	$72.4M+35.2%	$53.6M0.0%	$53.6M0.0%	$53.6M0.0%	$53.6M0.0%	$53.6M-28.0%	$74.4M+1.8%	$73.1M
Total Liabilities	$400.6M+2.7%	$390.2M+19.5%	$326.6M+168.2%	$121.8M-12.8%	$139.7M-17.3%	$169.0M+0.6%	$168.0M+28.0%	$131.2M+20.7%	$108.7M+0.1%	$108.6M-1.2%	$109.9M+17.8%	$93.3M-19.6%	$116.1M+7.4%	$108.1M-72.5%	$393.3M
Current Liabilities	$170.5M+1.1%	$168.6M+2.1%	$165.2M+97.6%	$83.6M-21.0%	$105.8M+1.9%	$103.9M+22.4%	$84.9M-1.2%	$85.9M+8.2%	$79.4M-4.8%	$83.4M+1.8%	$82.0M+23.4%	$66.4M-5.6%	$70.3M+7.7%	$65.3M-64.4%	$183.7M
Non-Current Liabilities	$230.1M+3.9%	$221.5M+37.3%	$161.4M+323.0%	$38.1M+12.7%	$33.9M-48.0%	$65.1M-21.7%	$83.1M+83.3%	$45.3M+54.5%	$29.3M+16.5%	$25.2M-9.8%	$27.9M+3.9%	$26.9M-41.2%	$45.8M+7.0%	$42.8M-79.6%	$209.6M
Long-Term Debt	$157.4M+0.2%	$157.0M+68.6%	$93.1M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A	N/A	N/A
Total Equity	$450.0M-10.6%	$503.1M-16.0%	$598.7M+77.7%	$336.9M0.0%	$336.9M-5.6%	$356.9M+8.9%	$327.6M-2.3%	$335.4M+13.1%	$296.6M+12.6%	$263.5M-9.2%	$290.3M-3.1%	$299.6M+1.3%	$295.9M-17.0%	$356.4M+27.2%	$280.3M
Retained Earnings	-$368.3M-33.4%	-$276.1M-83.9%	-$150.1M-12101.9%	$1.3M-94.0%	$21.0M-64.6%	$59.4M+2.8%	$57.7M-33.7%	$87.1M+23.7%	$70.4M+9.7%	$64.2M+2.6%	$62.6M-4.3%	$65.4M-11.6%	$73.9M-28.1%	$102.7M+42.6%	$72.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$873.0M+4.3%	$886.6M+7.7%	$850.6M-4.8%	$832.6M-4.1%	$837.2M-5.1%	$823.1M-9.2%	$893.3M-3.5%	$867.9M-4.2%
Current Assets	$446.1M+12.7%	$461.5M+18.2%	$416.8M-3.8%	$394.2M+2.1%	$395.8M+2.5%	$390.3M-2.2%	$433.3M+3.1%	$386.2M-1.9%
Cash & Equivalents	$103.8M+58.2%	$120.3M+107.5%	$82.0M-1.5%	$62.9M+109.2%	$65.6M+148.8%	$58.0M+114.9%	$83.2M+151.4%	$30.1M-10.7%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$184.5M+6.6%	$177.8M+1.9%	$172.3M-9.0%	$174.0M-15.4%	$173.0M-17.6%	$174.5M-20.4%	$189.5M-14.7%	$205.8M-7.2%
Accounts Receivable	$135.8M+4.8%	$137.8M+4.5%	$135.7M+0.8%	$130.8M+4.8%	$129.6M+3.3%	$131.9M+5.0%	$134.7M+5.2%	$124.8M+9.4%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$194.9M0.0%	$194.9M0.0%	$194.9M0.0%	$194.9M0.0%	$194.9M0.0%	$194.9M0.0%	$194.9M0.0%	$194.9M+0.1%
Total Liabilities	$443.8M+17.2%	$451.4M+23.7%	$400.6M+2.7%	$390.1M+14.1%	$378.8M+12.7%	$364.9M+8.7%	$390.2M+19.5%	$341.9M+17.8%
Current Liabilities	$157.0M+5.8%	$161.0M+11.7%	$170.5M+1.1%	$159.8M-1.3%	$148.4M-4.9%	$144.1M-4.3%	$168.6M+2.1%	$161.9M+6.1%
Non-Current Liabilities	$286.8M+24.5%	$290.4M+31.6%	$230.1M+3.9%	$230.3M+27.9%	$230.4M+28.0%	$220.7M+19.2%	$221.5M+37.3%	$180.1M+30.8%
Long-Term Debt	$221.6M+41.1%	$221.3M+41.1%	$157.4M+0.2%	$157.2M+40.1%	$157.0M+38.6%	$156.9M+36.3%	$157.0M+68.6%	$112.2M+60.3%
Total Equity	$429.2M-6.4%	$435.2M-5.0%	$450.0M-10.6%	$442.5M-15.9%	$458.3M-16.1%	$458.3M-19.6%	$503.1M-16.0%	$525.9M-14.6%
Retained Earnings	-$405.0M-18.0%	-$389.2M-18.2%	-$368.3M-33.4%	-$366.1M-48.2%	-$343.3M-56.3%	-$329.2M-76.9%	-$276.1M-83.9%	-$247.0M-93.0%

OFIX Cash Flow Statement

OFIX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$16.3M	$33.3M+29.3%	$25.8M+156.4%	-$45.8M-296.5%	-$11.5M-162.5%	$18.5M-75.1%	$74.3M+131.9%	$32.0M-35.8%	$49.9M+28.1%	$39.0M-34.0%	$59.1M+35.5%	$43.6M-14.8%	$51.2M-23.7%	$67.0M+559.7%	$10.2M-84.3%	$64.7M
Depreciation & Amortization	N/A	$77.3M+28.7%	$60.1M+13.2%	$53.1M+82.9%	$29.0M-2.0%	$29.6M-3.1%	$30.5M+23.7%	$24.7M+32.4%	$18.7M-7.3%	$20.1M-3.4%	$20.8M-0.4%	$20.9M-8.5%	$22.9M+0.2%	$22.8M+24.7%	$18.3M-21.1%	$23.2M
Stock-Based Compensation	N/A	$28.7M-11.6%	$32.5M-9.1%	$35.7M+93.6%	$18.4M+19.5%	$15.4M-4.8%	$16.2M-24.8%	$21.5M+13.8%	$18.9M+50.8%	$12.6M-21.4%	$16.0M+121.3%	$7.2M+26.0%	$5.7M-8.7%	$6.3M-0.6%	$6.3M-5.2%	$6.6M
Capital Expenditures	$44.1M	$34.6M-0.7%	$34.9M-42.1%	$60.3M+182.0%	$21.4M+20.1%	$17.8M+14.9%	$15.5M-18.5%	$19.0M+39.8%	$13.6M-7.3%	$14.7M-10.8%	$16.4M-39.6%	$27.2M+50.5%	$18.1M-27.1%	$24.8M-11.5%	$28.0M+12.1%	$25.0M
Free Cash Flow	-$27.8M	-$1.3M+85.9%	-$9.1M+91.4%	-$106.0M-222.2%	-$32.9M-4868.4%	$690K-98.8%	$58.8M+351.0%	$13.0M-64.1%	$36.3M+49.4%	$24.3M-43.0%	$42.6M+159.8%	$16.4M-50.4%	$33.1M-21.7%	$42.3M+337.0%	-$17.8M-144.8%	$39.8M
Investing Cash Flow	-$43.9M	-$34.6M-25.4%	-$27.6M+16.8%	-$33.1M-35.0%	-$24.5M-6.6%	-$23.0M+56.0%	-$52.3M-128.3%	-$22.9M+62.4%	-$61.0M-270.3%	-$16.5M+24.9%	-$21.9M+42.8%	-$38.3M-92.2%	-$19.9M+35.8%	-$31.1M	N/A	-$31.0M
Financing Cash Flow	$63.6M	-$786K-101.6%	$50.7M-22.4%	$65.3M+83846.2%	-$78K+97.8%	-$3.6M-211.6%	$3.2M+130.4%	-$10.7M-457.1%	$3.0M-15.4%	$3.5M+107.7%	-$46.1M-286.5%	$24.7M+222.4%	-$20.2M+47.3%	-$38.4M	N/A	-$13.7M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$63.4M+447.9%	$11.6M	N/A	$39.5M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$6.2M-153.5%	-$17.6M+4.2%	$27.7M+16.7%	$12.4M+6.3%	$11.6M+29.6%	-$18.4M+1.1%	$23.7M+454.5%	$11.7M+2346.8%
Depreciation & Amortization	$13.3M-21.3%	$13.5M-60.8%	$13.1M-18.2%	$12.9M-14.7%	$16.9M+20.2%	$34.4M+131.7%	$16.0M+14.5%	$15.2M+15.9%
Stock-Based Compensation	$7.7M-1.1%	$6.5M+1.0%	N/A	$7.2M+10.0%	$7.8M-21.4%	$6.5M-26.5%	N/A	$6.5M+4.1%
Capital Expenditures	$12.6M+77.9%	$10.7M+58.3%	$10.9M+27.5%	$9.9M+70.4%	$7.1M-28.8%	$6.7M-36.1%	$8.5M-41.4%	$5.8M-73.4%
Free Cash Flow	-$18.9M-516.6%	-$28.3M-12.5%	$16.8M+10.7%	$2.5M-57.4%	$4.5M+550.3%	-$25.1M+13.8%	$15.2M+171.5%	$5.9M+127.4%
Investing Cash Flow	-$12.6M-78.2%	-$10.5M-56.1%	-$10.9M-857.8%	-$9.9M-68.8%	-$7.1M+27.0%	-$6.7M+38.0%	-$1.1M+92.5%	-$5.9M+73.8%
Financing Cash Flow	$2.5M-7.2%	$64.0M+9926.4%	$2.4M-92.5%	-$5.2M-109.8%	$2.6M+1073.3%	-$651K-103.0%	$31.5M+24.6%	-$2.5M-113.5%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

OFIX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OFIX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	68.8%+0.6pp	68.3%+3.1pp	65.1%-8.1pp	73.2%-2.1pp	75.3%+0.3pp	74.9%-3.2pp	78.1%-0.5pp	78.7%+0.1pp	78.5%0.0pp	78.6%+0.4pp	78.2%+2.8pp	75.4%+2.3pp	73.1%-4.0pp	77.1%-0.7pp	77.9%
Operating Margin	-9.9%+0.7pp	-10.6%+8.0pp	-18.6%-15.8pp	-2.9%-1.1pp	-1.8%-0.2pp	-1.5%+2.5pp	-4.1%-10.7pp	6.6%-2.8pp	9.4%+4.3pp	5.1%+2.8pp	2.3%-1.9pp	4.3%+7.1pp	-2.8%-19.8pp	17.0%+15.5pp	1.5%
Net Margin	-11.2%+4.5pp	-15.8%+4.5pp	-20.3%-16.0pp	-4.3%+4.0pp	-8.3%-8.9pp	0.6%+6.8pp	-6.2%-9.2pp	3.0%+1.6pp	1.4%+0.7pp	0.8%+1.5pp	-0.7%+1.4pp	-2.1%+5.1pp	-7.2%-17.0pp	9.7%+13.8pp	-4.1%
Return on Equity	-20.5%+4.6pp	-25.0%+0.3pp	-25.3%-19.4pp	-5.9%+5.5pp	-11.4%-12.1pp	0.7%+9.4pp	-8.7%-12.8pp	4.1%+2.0pp	2.1%+0.9pp	1.2%+2.1pp	-1.0%+1.9pp	-2.9%+6.9pp	-9.7%-21.8pp	12.0%+18.3pp	-6.3%
Return on Assets	-10.8%+3.3pp	-14.1%+2.2pp	-16.4%-12.0pp	-4.3%+3.7pp	-8.1%-8.5pp	0.5%+6.2pp	-5.7%-8.7pp	3.0%+1.4pp	1.5%+0.7pp	0.8%+1.5pp	-0.7%+1.5pp	-2.2%+4.8pp	-7.0%-16.2pp	9.2%+11.8pp	-2.6%
Current Ratio	2.45-0.1x	2.570.0x	2.54-0.5x	3.06+0.5x	2.55-0.1x	2.60-0.5x	3.07+0.2x	2.85-0.3x	3.17+0.8x	2.33-0.3x	2.59-0.7x	3.30-0.5x	3.77-0.8x	4.60+1.7x	2.89
Debt-to-Equity	0.350.0x	0.31+0.2x	0.16-0.2x	0.36-0.1x	0.41-0.1x	0.470.0x	0.51+0.1x	0.390.0x	0.370.0x	0.410.0x	0.38+0.4x	0.00-0.4x	0.39+0.1x	0.30-1.1x	1.40
Asset Turnover	0.97+0.1x	0.90+0.1x	0.81-0.2x	1.000.0x	0.97+0.2x	0.77-0.2x	0.930.0x	0.97-0.1x	1.070.0x	1.10+0.1x	0.990.0x	1.02+0.1x	0.970.0x	0.95+0.3x	0.64
FCF Margin	-0.2%+1.0pp	-1.1%+13.1pp	-14.2%-7.1pp	-7.1%-7.3pp	0.1%-14.3pp	14.5%+11.6pp	2.8%-5.2pp	8.0%+2.4pp	5.6%-4.8pp	10.4%+6.3pp	4.1%-4.1pp	8.2%-2.4pp	10.6%+14.7pp	-4.0%-13.2pp	9.1%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	71.0%+2.3pp	70.9%+8.1pp	71.1%+2.1pp	72.2%+3.5pp	68.7%+0.8pp	62.8%-4.7pp	69.0%+0.9pp	68.7%+3.6pp
Operating Margin	-3.9%+4.0pp	-7.3%+17.9pp	0.2%+5.5pp	-8.3%+1.3pp	-7.9%+4.7pp	-25.2%-9.7pp	-5.3%+3.8pp	-9.6%+3.7pp
Net Margin	-7.5%-0.6pp	-10.6%+16.8pp	-1.0%+12.5pp	-11.1%+2.8pp	-6.9%+9.9pp	-27.4%-8.3pp	-13.5%-2.4pp	-13.9%+1.7pp
Return on Equity	-3.7%-0.6pp	-4.8%+6.8pp	-0.5%+5.3pp	-5.1%+0.1pp	-3.1%+3.1pp	-11.6%-5.3pp	-5.8%-2.1pp	-5.2%-0.5pp
Return on Assets	-1.8%-0.1pp	-2.4%+4.1pp	-0.3%+3.0pp	-2.7%+0.4pp	-1.7%+2.1pp	-6.5%-2.5pp	-3.3%-0.9pp	-3.2%0.0pp
Current Ratio	2.84+0.2x	2.87+0.2x	2.45-0.1x	2.47+0.1x	2.67+0.2x	2.71+0.1x	2.570.0x	2.39-0.2x
Debt-to-Equity	0.52+0.2x	0.51+0.2x	0.350.0x	0.36+0.1x	0.34+0.1x	0.34+0.1x	0.31+0.2x	0.21+0.1x
Asset Turnover	0.240.0x	0.220.0x	0.260.0x	0.250.0x	0.240.0x	0.240.0x	0.240.0x	0.230.0x
FCF Margin	-8.9%-11.2pp	-14.4%-1.4pp	7.6%+0.6pp	1.2%-1.8pp	2.2%+2.7pp	-13.0%+2.5pp	7.0%+17.7pp	3.0%+14.6pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Orthofix Medical Inc. OFIX	FY2025	$822.3M	-$92.2M	-11.2%	$373.5M	43/100
Avanos Medical, Inc. AVNS	FY2025	$701.2M	-$72.9M	-10.4%	$1.2B	44/100
Bioventus Inc. BVS	FY2025	$568.1M	$22.7M	4.0%	$892.4M	42/100
SI-BONE, Inc. SIBN	FY2025	$200.9M	-$18.9M	-9.4%	$868.1M	53/100
ZimVie Inc. ZIMV	FY2024	$449.7M	-$25.8M	-5.7%	$535.7M	23/100
OrthoPediatrics Corp. KIDS	FY2025	$236.3M	-$39.6M	-16.8%	$565.3M	56/100

Where Orthofix Medical Inc. Ranks

Frequently Asked Questions

What is Orthofix Medical Inc.'s annual revenue?

Orthofix Medical Inc. (OFIX) reported $822.3M in total revenue for fiscal year 2025. This represents a 2.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Orthofix Medical Inc.'s revenue growing?

Orthofix Medical Inc. (OFIX) revenue grew by 2.9% year-over-year, from $799.5M to $822.3M in fiscal year 2025.

Is Orthofix Medical Inc. profitable?

No, Orthofix Medical Inc. (OFIX) reported a net income of -$92.2M in fiscal year 2025, with a net profit margin of -11.2%.

What is Orthofix Medical Inc.'s EBITDA?

Orthofix Medical Inc. (OFIX) had EBITDA of -$4.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Orthofix Medical Inc. have?

As of fiscal year 2025, Orthofix Medical Inc. (OFIX) had $82.0M in cash and equivalents against $157.4M in long-term debt.

What is Orthofix Medical Inc.'s gross margin?

Orthofix Medical Inc. (OFIX) had a gross margin of 68.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Orthofix Medical Inc.'s operating margin?

Orthofix Medical Inc. (OFIX) had an operating margin of -9.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Orthofix Medical Inc.'s net profit margin?

Orthofix Medical Inc. (OFIX) had a net profit margin of -11.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Orthofix Medical Inc.'s return on equity (ROE)?

Orthofix Medical Inc. (OFIX) has a return on equity of -20.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Orthofix Medical Inc.'s free cash flow?

Orthofix Medical Inc. (OFIX) recorded an outflow of $1.3M in free cash flow during fiscal year 2025. This represents a 85.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Orthofix Medical Inc.'s operating cash flow?

Orthofix Medical Inc. (OFIX) generated $33.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Orthofix Medical Inc.'s total assets?

Orthofix Medical Inc. (OFIX) had $850.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Orthofix Medical Inc.'s capital expenditures?

Orthofix Medical Inc. (OFIX) invested $34.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Orthofix Medical Inc. spend on research and development?

Orthofix Medical Inc. (OFIX) invested $65.8M in research and development during fiscal year 2025.

How many shares does Orthofix Medical Inc. have outstanding?

Orthofix Medical Inc. (OFIX) had 40M shares outstanding as of fiscal year 2025.

What is Orthofix Medical Inc.'s current ratio?

Orthofix Medical Inc. (OFIX) had a current ratio of 2.45 as of fiscal year 2025, which is generally considered healthy.

What is Orthofix Medical Inc.'s debt-to-equity ratio?

Orthofix Medical Inc. (OFIX) had a debt-to-equity ratio of 0.35 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Orthofix Medical Inc.'s return on assets (ROA)?

Orthofix Medical Inc. (OFIX) had a return on assets of -10.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Orthofix Medical Inc.'s P/E ratio?

Orthofix Medical Inc. (OFIX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $373.5M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Orthofix Medical Inc.'s price-to-sales ratio?

Orthofix Medical Inc. (OFIX) trades at 0.4x sales, its market capitalization divided by revenue of $833.2M revenue, trailing 12 months to June 30, 2026. The market capitalization is $373.5M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Orthofix Medical Inc.'s Altman Z-Score?

Orthofix Medical Inc. (OFIX) has an Altman Z-Score of 0.95, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Orthofix Medical Inc.'s Piotroski F-Score?

Orthofix Medical Inc. (OFIX) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Orthofix Medical Inc.'s earnings high quality?

Orthofix Medical Inc. (OFIX) reported a net loss of $92.2M while generating $33.3M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Orthofix Medical Inc. cover its interest payments?

Orthofix Medical Inc. (OFIX) reported an operating loss of $81.4M against $17.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Orthofix Medical Inc.?

Orthofix Medical Inc. (OFIX) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.